Gone are the bear days for biotech? William Blair thinks so

After a 12 months marked by dramatic ups and downs, William Blair analysts say 2026 may carry ahead the business’s present momentum—so long as robust scientific knowledge proceed to be rewarded and firms can carry medication to market with out main authorities pricing laws.

This 12 months has been outlined by deep uncertainty, largely rooted in federal actions occurring below President Donald Trump after he took workplace for the second time. The XBI—a efficiency tracker for U.S. biotech firms—began the 12 months with a 20% drop-off, bottoming out April 4 at $66. The low succeeded Trump’s Liberation Day Tariffs introduced April 2.  

“At that time, investor sentiment was extraordinarily poor, as political headwinds continued a multiyear underperformance of the sector, notably compared to the continued energy of the tech sector,” William Blair analysts wrote in a Dec. 10 observe.

However, since April, the biotech-specific index has recovered, climbing practically 75% to hit ranges that haven’t been reached for the reason that finish of 2021.

Deep market uncertainty nonetheless exists, notably centered round U.S. drug pricing and altering dynamics on the FDA, with solely three senior leaders in place from a 12 months in the past. Given the continued adjustments on the company and “lack of scientific rigor in discussions about vaccine laws,” the analysts don’t see the associated uncertainty disappearing in 2026.

William Blair pointed to sure FDA efforts which have optimistic implications, like releasing redacted full response letters, however underscored that essentially the most very important consideration for buyers is consistency in regulatory requirements for opinions. 

The analysts additionally highlighted the rising danger that China may overtake the nation’s biopharma place, noting the growing stage of M&A involving Chinese language property is unlikely to fade.

Regardless of these traits, William Blair believes “continued robust scientific knowledge, business launches and M&A will hold the sector performing higher than the bear markets of 2021 by 2024.”

That’s to not say the aforementioned dangers are gone, however, as an alternative, that almost all buyers “consider the worst-case eventualities are off the desk,” William Blair analysts wrote, citing commitments to onshoring manufacturing and the decision of among the “largest” fears associated to Trump’s most-favored nation coverage.

The analyst’s optimism can also be rooted in continued M&A exercise, with 2025 recording essentially the most deal quantity for the sector within the final decade. As of mid-December, the sector noticed slightly below 70 offers with a disclosed worth of $20 million or extra.

The shortage of enormous M&A offers means 2025’s complete deal worth nonetheless falls beneath many previous years, however William Blair thinks the general quantity has boosted investor sentiment. The uptick additionally helps the concept Massive Pharmas want dealmaking to bolster their pipelines, particularly as giant patent cliffs loom.   

For 2026, William Blair analysts consider the sector can keep many of the momentum, although the agency doesn’t suppose “the XBI as an entire must meaningfully outperform,” citing index-specific limitations similar to its larger-cap bias.

“So long as the sector continues to reward robust scientific outcomes and firms are capable of commercially launch medication with out vital authorities laws round pricing, we consider specialist funding in biotech can proceed to have robust efficiency,” the analysts concluded.